Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.625 +0.165 (+3.70%)
Streaming Delayed Price Updated: 2:05 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
Via Stocktwits
Topics Intellectual Property
News headline image
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based... 
Via Finterra
Topics Initial Public Offering Intellectual Property Lawsuit
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Via Chartmill
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period... 
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the... 
Via PredictStreet
Topics Initial Public Offering Intellectual Property
News headline image
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum ↗
Arbutus Biopharma (ABUS) shows strong technical health and high-growth momentum, with surging sales and earnings, positioning it for potential gains. 
Via Chartmill
News headline image
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus (ABUS) Q2 Revenue Surges 529% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Provides 2025 Corporate and Financial Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
From Whitefort Capital Management, LP
Via Business Wire
News headline image
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine ↗
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible... 
Via Benzinga
Topics Intellectual Property
News headline image
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.